Single-cell RNA-seq analysis across clear cell RCC disease states revealed that terminally exhausted CD8+ T cells and M2-like tumor associated macrophages were enriched in advanced RCC and associated with disease progression to nivolumab.16,17 Thus, there is a need to maximally target these resistant cells upfront to prevent disease progression and optimize the immune response. The gene discussed is CD8A; the disease is neoplasm.